Westover Capital Advisors LLC Cuts Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Westover Capital Advisors LLC trimmed its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 84,576 shares of the biopharmaceutical company’s stock after selling 942 shares during the quarter. Westover Capital Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $1,422,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Parkside Financial Bank & Trust bought a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $31,000. Nisa Investment Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 306.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 3,829 shares during the period. Sherbrooke Park Advisers LLC bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at $123,000. PNC Financial Services Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 42.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 11,241 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 3,354 shares during the period. Finally, CenterBook Partners LP lifted its holdings in shares of Catalyst Pharmaceuticals by 20.0% during the 3rd quarter. CenterBook Partners LP now owns 13,577 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 2,259 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Bank of America assumed coverage on Catalyst Pharmaceuticals in a report on Thursday, March 7th. They set a “buy” rating and a $23.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $24.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, March 1st. StockNews.com raised Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. TheStreet raised Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a report on Tuesday, March 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $34.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, March 22nd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $26.43.

Catalyst Pharmaceuticals Trading Down 1.1 %

Catalyst Pharmaceuticals stock traded down $0.17 during trading on Thursday, reaching $15.03. The company had a trading volume of 481,600 shares, compared to its average volume of 1,439,936. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.09 and a 52 week high of $17.76. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 24.69, a price-to-earnings-growth ratio of 0.83 and a beta of 0.89. The firm’s 50-day simple moving average is $15.62 and its 200 day simple moving average is $14.68.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.04. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%. The business had revenue of $110.57 million during the quarter, compared to analyst estimates of $105.78 million. On average, analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.81 earnings per share for the current year.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 25,000 shares of the stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $16.44, for a total value of $411,000.00. Following the completion of the sale, the insider now owns 124,433 shares in the company, valued at approximately $2,045,678.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.